Exploratory Trial to Assess Mechanism of Action, Clinical Effect, Safety and Tolerability of 12 Weeks of Treatment With BI 655130 in Patients With Active Ulcerative Colitis (UC)
Phase of Trial: Phase II
Latest Information Update: 30 Jul 2018
At a glance
- Drugs BI 655130 (Primary)
- Indications Ulcerative colitis
- Focus Pharmacodynamics
- Sponsors Boehringer Ingelheim
- 29 Jun 2018 This study has been changed from suspended to recruiting in Germany.
- 31 May 2018 Planned End Date changed from 5 Mar 2019 to 14 Jun 2019.
- 31 May 2018 Planned primary completion date changed from 13 Nov 2018 to 22 Feb 2019.